## Prevention and Risk Factors for Neural Tube Defects ### Folic Acid Supplementation **High-Yield:** Periconceptional folic acid supplementation is the cornerstone of NTD prevention: - **Standard dose:** 400 μg daily reduces NTD risk by **50–70%** in the general population - **High-risk dose:** **5 mg daily** for women with: - Previous NTD pregnancy - Family history of NTD - Maternal diabetes or epilepsy - Antiepileptic drug use - Supplementation must begin **at least 4 weeks before conception** and continue through the **first trimester** (critical period for neural tube closure: weeks 3–4) ### Maternal Diabetes and NTD Risk **Clinical Pearl:** Maternal hyperglycemia in the first trimester is a well-established risk factor for NTDs: - Risk increases with poor glycemic control (elevated HbA1c) - Tight preconception glycemic control (target HbA1c < 6.5%) significantly reduces NTD risk - Mechanism: hyperglycemia impairs cell migration and differentiation during neurulation ### Anticonvulsants and NTD Risk **Key Point:** Phenytoin, valproate, and other antiepileptic drugs (AEDs) increase NTD risk, **BUT NOT by directly inhibiting neural tube closure via calcium channel blockade**. **Mechanism of AED-induced NTD:** - Phenytoin: inhibits folate metabolism and increases folate requirements - Valproate: causes histone deacetylase inhibition, disrupting gene expression during neurulation - Carbamazepine: similar folate antagonism - The mechanism is **metabolic disruption and gene dysregulation**, NOT direct calcium channel blockade **Warning:** Option 4 incorrectly attributes the mechanism to calcium channel blockade, which is not the established pathophysiology of AED-induced NTDs. ## Summary Table: NTD Risk Factors and Prevention | Risk Factor | Mechanism | Prevention Strategy | | --- | --- | --- | | Low folate intake | Impaired nucleotide synthesis | 400 μg folic acid (standard) or 5 mg (high-risk) | | Maternal diabetes | Hyperglycemia-induced metabolic disruption | Preconception glycemic control (HbA1c < 6.5%) | | Antiepileptic drugs | Folate antagonism, histone deacetylase inhibition | High-dose folic acid (5 mg) + seizure control optimization | | Maternal obesity | Reduced folate bioavailability | Weight loss before conception + folic acid | | Valproate use | Histone deacetylase inhibition, teratogenic | Avoid if possible; if essential, use lowest effective dose | [cite:Harrison 21e Ch 297; Park 26e Ch 3]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.